Crossmark

Engineered Dual-Component Lipid-Polymer Nanoparticles for Modified Olanzapine Release, Shelf-Life Assessment, and Elevated Bioavailability in Schizophrenia Therapy

Crossref DOI link: https://doi.org/10.1007/s12247-025-10132-2

Published Online: 2025-10-17

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raysing, Swati

Chillarge, Aniket

Katolkar, Ujwal

Mali, Krunal
License Information

Text and Data Mining valid from 2025-10-17

Version of Record valid from 2025-10-17
More Information

Article History

Received: 3 July 2025

Accepted: 9 September 2025

First Online: 17 October 2025

Declarations

:

: The authors declare no competing interests.

: During the preparation of this work, the author(s) used ChatGPT in order to check and correct grammar in sentences. After using this tool/service, the author(s) reviewed and edited the content as needed and take full responsibility for the content of the publication.

Document is current

Any future updates will be listed below